Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate; povidone; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; macrogol 3350 - voriconazole-medis is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: povidone; crospovidone; sodium carbonate; magnesium stearate; microcrystalline cellulose; glycerol dibehenate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ,atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium trihydrate, quantity: 86.8 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glycerol dibehenate; magnesium stearate; crospovidone; povidone; sodium carbonate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ,atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - ondansetron hydrochloride, quantity: 4.98 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; water for injections; sodium citrate dihydrate - prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. prevention and treatment of postoperative nausea and vomiting.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; hydrogenated castor oil; colloidal anhydrous silica; maize starch - irbesartan hct medis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - mometasone furoate, quantity: 1 mg/g - ointment - excipient ingredients: hexylene glycol; white soft paraffin; white beeswax; propylene glycol monostearate - mometasone medis ointment is indicated for short-term (up to 4 continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, such as psoriasis and atopic dermatitis.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - mometasone furoate, quantity: 1 mg/g - cream - excipient ingredients: stearyl alcohol; propylene glycol monostearate; aluminium starch octenylsuccinate; titanium dioxide; ceteareth-20; white soft paraffin; propylene glycol; purified water; phosphoric acid; white beeswax - mometasone medis cream is indicated for short-term (up to 4 continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, such as psoriasis and atopic dermatitis.

Malezija - angleščina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - calcium carbonate; cholecalciferol; vitamin k2 -